Villejuif

• A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors Ended recruitment
  2023-509605-77-00 1 2019-06-27 Advanced solid tumours
• OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN A … Ended recruitment
  2024-516048-24-00 4 2019-06-19 CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST
• A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer. Ended recruitment
  2023-508264-29-00 5 2019-06-11 Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto … Ended recruitment
  2023-504932-16-00 5 2019-06-04 Muscle Invasive Bladder Cancer
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• A Phase 3 Study to compare how effective and safe DCC-2618 is versus sunitinib in patients with GIST who have been treated previously with i … Ended recruitment
  2024-513277-52-00 5 2019-05-20 Patients with Advanced Gastrointestinal Stromal Tumors
• Study of durvalumab or placebo administered with radiation therapy for patients with early stage non-small cell lung cancer Study of osime … Ended recruitment
  2024-512667-31-00 5 2019-04-23 Main cohort: Patients with unresected Stage I/II, lymph-node negative
• TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT … Ended recruitment
  2023-509087-20-00 5 2019-04-16 Metastatic Castration-resistant Prostate Cancer
• This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre … Ended recruitment
  2023-509349-11-00 5 2019-03-22 Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
• A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer Ended recruitment
  2024-510985-17-00 4 2019-03-14 First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Amivantamab (JNJ61186372), a Human Bispecific EGFR and cMet Antibody, in Par … Ended recruitment
  2023-509435-11-00 1 2019-02-21 Advanced Non-Small Cell Lung Cancer
• Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Ended recruitment
  2023-503812-34-00 4 2019-02-13 Locally Advanced or Metastatic Disease in Solid Tumors
• Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended recruitment
  2024-511204-16-00 5 2019-01-23 Metastatic breast cancer
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended recruitment
  2023-506921-12-00 5 2018-12-27 ER+/HER2- Breast Cancer
• MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo … Ended recruitment
  2022-500254-41-00 5 2018-12-13 Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamou
• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended recruitment
  2023-505376-30-00 4 2018-10-30 BRAF V600 mutation–positive unresectable or metastatic melanoma
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended recruitment
  2024-513206-65-00 5 2018-08-10 resected squamous cell carcinoma of head and neck
• A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re … Ended recruitment
  2023-506861-76-00 5 2018-08-09 Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplasti
• A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300 … Ended recruitment
  2023-506541-39-00 1 2018-08-03 Small Cell Lung Cancer
• A clinical trial aiming to assess the effect of an immunotherapy for the treatment of soft tissue sarcomas treated by radiotherapy Ended recruitment
  2024-510713-15-00 4 2018-07-30 Localised and operable soft tissue sarcomas
• Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocri … Ended recruitment
  2023-505286-84-00 4 2018-06-25 Pancreatic well differentiated neuroendocrine tumors (NET)

Showing 697–720 of 961 trials